Last updated: August 1, 2026
Micronor is a norethindrone 0.35 mg progestin-only oral contraceptive. Its commercial value is limited by long-established generic competition, the absence of meaningful current patent protection, and the availability of alternative progestin-only pills, hormonal intrauterine systems, implants, injections and combined oral contraceptives. No active clinical-development program is associated with Micronor as a branded innovation product. Market growth is more likely to track demand for progestin-only contraception than Micronor itself.
What is Micronor and what is its FDA status?
Micronor contains norethindrone 0.35 mg and is indicated for the prevention of pregnancy. It is a progestin-only pill, often called a POP or “mini-pill.” Unlike combined oral contraceptives, it does not contain estrogen.
| Attribute |
Micronor |
| Active ingredient |
Norethindrone |
| Strength |
0.35 mg |
| Dosage form |
Oral tablet |
| Therapeutic class |
Progestin-only contraceptive |
| Regulatory pathway |
Original NDA product with generic ANDA competition |
| U.S. regulatory status |
FDA-approved product category |
| Primary use |
Pregnancy prevention |
| Estrogen content |
None |
| Prescription status |
Prescription contraceptive |
| Reference product NDA |
NDA 017342, as identified in FDA labeling materials |
| Biosimilar relevance |
None |
The product label instructs patients to take one tablet daily at the same time without a tablet-free interval. Norethindrone POPs depend heavily on adherence because delays in daily dosing can reduce contraceptive protection. The FDA labeling also identifies irregular bleeding, spotting and amenorrhea as common clinical issues associated with progestin-only contraception (U.S. Food and Drug Administration, 2024).
What clinical trials are evaluating Micronor?
Micronor does not have a current late-stage clinical-trial program comparable to a newly developed contraceptive product. The drug has an established safety and efficacy history, and regulatory activity is centered on labeling, manufacturing and generic substitution rather than new efficacy development.
ClinicalTrials.gov contains studies involving norethindrone and progestin-only contraception, but these studies generally evaluate broader contraceptive strategies, postpartum contraception, adherence, bleeding patterns, reproductive health or comparisons with other methods. They should not be treated as Micronor-sponsored pivotal trials unless the study specifically identifies Micronor as the investigational product or comparator (National Library of Medicine, n.d.).
What clinical evidence supports norethindrone 0.35 mg?
The clinical evidence base for norethindrone POPs includes:
- Contraceptive effectiveness studies involving norethindrone tablets.
- Postpartum and breastfeeding studies.
- Research on irregular bleeding and treatment continuation.
- Comparative studies of progestin-only and combined hormonal contraception.
- Pharmacology and adherence studies involving daily oral norethindrone.
Micronor’s clinical position depends less on new efficacy findings than on predictable use in patients who cannot use estrogen or prefer an estrogen-free method. Its main limitations are strict daily dosing requirements and less predictable bleeding than some long-acting reversible contraceptives.
Are new trials likely to materially change Micronor’s market position?
A new trial is unlikely to create substantial differentiation for Micronor because norethindrone 0.35 mg is an established, low-cost active ingredient. Trials involving newer progestin-only pills, longer missed-pill windows, improved bleeding control or over-the-counter access are more commercially relevant to the category than trials of Micronor itself.
What patents protect Micronor?
Micronor has no commercially significant current U.S. patent barrier comparable to those protecting newer branded contraceptives. The product was introduced decades ago, and its core composition and immediate-release tablet technology are subject to extensive prior art and generic competition.
| Protection category |
Micronor position |
| Active-ingredient patent |
No meaningful current exclusivity expected |
| Core composition patent |
Historical protection, if any, has expired |
| Immediate-release tablet patent |
No significant current barrier identified |
| Method-of-use patent |
No meaningful current barrier identified |
| Device or delivery-system patent |
Not applicable |
| Manufacturing-process barrier |
Routine pharmaceutical manufacturing |
| Regulatory exclusivity |
Expired |
| Generic substitution risk |
High |
The relevant commercial distinction is between the Micronor brand and norethindrone 0.35 mg generics. Generic manufacturers can compete through abbreviated new drug applications when they establish pharmaceutical equivalence and bioequivalence to the reference product. A generic does not need to reproduce the brand’s commercial identity.
What is the Orange Book status of Micronor?
The FDA Orange Book identifies reference-listed drugs and approved generic equivalents. Micronor’s practical Orange Book value is as a historical reference product for norethindrone 0.35 mg tablets rather than as an actively protected branded asset.
Orange Book listings can change based on marketing status, sponsor updates, product discontinuation determinations and FDA database maintenance. A product may remain relevant as a reference standard even when the branded product has limited commercial distribution. The existence of an Orange Book listing does not establish that an unexpired patent protects the product.
For generic applicants, the central issues are usually:
- Whether the reference product remains eligible for ANDA reliance.
- Whether FDA considers the product therapeutically equivalent.
- Whether any listed patent or regulatory exclusivity remains active.
- Whether commercial supply and manufacturing economics support launch.
When does Micronor lose exclusivity?
Micronor’s principal exclusivity expired long ago. The product does not have the commercial profile of a recently approved drug with active five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity or patent-term-restoration protection.
| Exclusivity type |
Micronor status |
| New chemical entity exclusivity |
Expired |
| Five-year NCE exclusivity |
Not commercially relevant today |
| Three-year clinical exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial effect |
| Orphan-drug exclusivity |
Not applicable |
| Patent-term extension |
No current barrier |
| Generic entry |
Established |
Norethindrone itself is an old active pharmaceutical ingredient. The key commercial question is therefore not when Micronor loses exclusivity, but how many suppliers remain active and whether they can manufacture the product profitably.
Which companies compete with Micronor?
Micronor competes with generic norethindrone products and with other contraceptive platforms. The most direct competitors are generic manufacturers that sell norethindrone 0.35 mg tablets. Supplier participation can change because of discontinuations, shortages, contract manufacturing changes and pharmacy purchasing decisions.
Broader competitors include:
| Competitor category |
Examples |
Competitive effect |
| Generic norethindrone POPs |
Multiple ANDA-approved products |
Direct price competition |
| Drospirenone POP |
Slynd |
Longer missed-pill window and different clinical profile |
| Levonorgestrel IUDs |
Mirena, Liletta, Kyleena, Skyla |
Long-acting contraception |
| Etonogestrel implant |
Nexplanon |
Long-acting contraception |
| Depot medroxyprogesterone acetate |
Depo-Provera and generics |
Injectable contraception |
| Combined oral contraceptives |
Numerous brands and generics |
Broad substitution |
| Nonhormonal methods |
Copper IUD, barrier methods |
Alternative mechanism |
Slynd is particularly relevant because it is an oral progestin-only option with a different active ingredient and dosing profile. Its commercial differentiation includes a four-day hormone-free interval and a longer missed-pill window than traditional norethindrone POPs. That differentiation supports a higher price than generic norethindrone but also exposes Slynd to active branded-product and patent risks not present for Micronor.
How strong is the Micronor patent estate?
The Micronor patent estate is weak from a commercial exclusivity perspective.
Composition and formulation protection
Norethindrone 0.35 mg immediate-release tablets use conventional pharmaceutical ingredients and manufacturing methods. The product does not depend on a proprietary extended-release system, implant, transdermal platform, complex device or biologic manufacturing process.
Method-of-use protection
No active method-of-use patent is expected to prevent generic use of norethindrone 0.35 mg for contraception. Any historical use patents would face expiration based on the product’s age and the long-established use of norethindrone in contraception.
Manufacturing and supply barriers
Manufacturing barriers are operational rather than intellectual-property based. They include:
- Sourcing pharmaceutical-grade norethindrone.
- Maintaining validated tablet manufacturing.
- Meeting dissolution and content-uniformity specifications.
- Maintaining FDA-compliant quality systems.
- Managing low-margin contract or generic production.
- Maintaining reliable distribution to wholesalers and pharmacies.
These barriers can affect supply continuity but do not provide durable market exclusivity.
Are there Paragraph IV challenges or Micronor patent lawsuits?
Micronor is not associated with a current high-value Paragraph IV litigation campaign. Paragraph IV certifications are most commercially important when a generic applicant challenges an unexpired patent listed for a branded product. Micronor’s age and generic availability reduce the likelihood that a new Paragraph IV case would materially affect the market.
No current litigation involving a Micronor patent estate is expected to alter generic access. Any historical ANDA disputes would have limited commercial relevance unless they involved an active patent, enforceable settlement restriction or supply agreement. The absence of meaningful active patent protection makes a traditional patent-settlement strategy less likely than routine generic competition.
What is the market size and revenue exposure for Micronor?
Micronor does not have a broadly disclosed standalone revenue base in public company reporting. Sales are commonly grouped within contraceptive, women’s-health or generic pharmaceutical revenue. A reliable Micronor-specific forecast therefore requires prescription, channel and net-price data that are not generally reported by the sponsor.
Revenue drivers
Micronor demand is influenced by:
- Use of estrogen-free contraception.
- Breastfeeding and postpartum prescribing.
- Contraindications to estrogen.
- Patient preference for oral contraception.
- Generic pricing and pharmacy substitution.
- Availability of newer progestin-only pills.
- Contraceptive access policies and insurance coverage.
- Manufacturer supply reliability.
Five-year market outlook
| Period |
Micronor-specific outlook |
Category outlook |
| 2025-2026 |
Stable to declining brand relevance |
Progestin-only demand remains supported |
| 2027-2028 |
Continued generic substitution |
Newer POPs may gain share |
| 2029-2030 |
Low probability of major branded growth |
Long-acting methods and newer oral products remain competitive |
The most probable scenario is low-single-digit annual erosion for the Micronor brand or branded-equivalent business, with generic norethindrone retaining demand as a low-cost option. The broader progestin-only contraceptive segment can grow faster than Micronor if access expands or if clinicians shift prescribing away from estrogen-containing products.
What generic launch risks exist for Micronor?
Generic launch risk is already realized rather than prospective. The main risks are commercial:
- Further price compression.
- Pharmacy substitution away from the brand.
- Manufacturer discontinuation.
- Supply interruptions caused by low margins.
- Competition from drospirenone POPs.
- Patient switching to long-acting contraception.
- Reduced prescribing when over-the-counter contraceptive access expands.
A generic manufacturer evaluating entry would face limited patent risk but potentially modest economic upside. The product is technically straightforward, and the major diligence questions concern market size, active competitors, API sourcing, FDA manufacturing compliance and reimbursement economics.
How does Micronor compare with Slynd?
| Factor |
Micronor |
Slynd |
| Active ingredient |
Norethindrone 0.35 mg |
Drospirenone 4 mg |
| Product type |
Progestin-only pill |
Progestin-only pill |
| Generic competition |
Established |
More limited, depending on jurisdiction and patent status |
| Dosing flexibility |
Narrower missed-pill window |
Longer missed-pill window |
| Price position |
Low-cost generic segment |
Branded premium segment |
| Patent exposure |
Low |
Higher |
| Clinical differentiation |
Established estrogen-free option |
Dosing and tolerability differentiation |
| Commercial outlook |
Mature/declining |
Growth potential with patent and reimbursement risk |
Micronor retains a cost advantage. Slynd has stronger product differentiation and a greater opportunity to capture patients who struggle with traditional norethindrone adherence.
What is the regulatory and commercial outlook for Micronor?
Micronor remains a mature FDA-approved contraceptive product with no evident pipeline catalyst. Its regulatory risk is primarily manufacturing and supply compliance, not clinical efficacy. Its commercial risk is substitution by generic norethindrone, newer progestin-only pills and long-acting contraceptive methods.
Licensing activity is unlikely to be material unless a company acquires a portfolio of women’s-health products, a generic manufacturer purchases distribution rights or a sponsor combines Micronor with a broader contraception-access strategy. The product’s value is more likely to arise from portfolio fit and reliable supply than from patent exclusivity.
Key Takeaways
- Micronor is a norethindrone 0.35 mg progestin-only contraceptive tablet.
- Its original regulatory exclusivity and any commercially important core patent protection have expired.
- Generic norethindrone competition is established, making Paragraph IV and patent-litigation risk low.
- No current Micronor-specific pivotal clinical program is expected to change its market position.
- Micronor’s main commercial advantages are low cost, established use and suitability for patients avoiding estrogen.
- Its main disadvantages are strict dosing requirements, irregular bleeding and competition from newer POPs and long-acting contraceptives.
- Micronor-specific revenue is not generally disclosed separately.
- The brand outlook is mature to declining, while the broader progestin-only contraception category has greater growth potential.
FAQs
Is Micronor the same as norethindrone?
Micronor is a branded product containing norethindrone 0.35 mg. Generic norethindrone 0.35 mg tablets are intended to be pharmaceutically equivalent to the reference product when approved by FDA.
Can Micronor be replaced by Slynd?
Both are progestin-only pills, but they contain different active ingredients and have different dosing instructions, contraindications and clinical profiles. Substitution requires a prescribing decision.
Does Micronor contain estrogen?
No. Micronor contains norethindrone, a progestin, and does not contain estrogen.
Is Micronor protected by orphan-drug exclusivity?
No. Contraception is not an orphan indication for Micronor, and orphan-drug exclusivity does not apply.
What is the biggest investment risk for a Micronor supplier?
The largest risk is margin erosion and supply instability in a mature generic market. Patent barriers are less important than manufacturing cost, API availability, reimbursement and pharmacy purchasing behavior.
References
-
U.S. Food and Drug Administration. (2024). Micronor: Norethindrone tablets, USP 0.35 mg prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
